Acral erythema is also known as a Hand-foot Syndrome (HFS), or palmar-plantar epidysesthesia. It causes swelling, redness and paraesthesia (numbness), as well skin peeling (skin peeling), of the hands, soles, elbows and knees. Acryl erythema can occur after prolonged treatment with chemotherapy medicines. The most common of these are fluorouracil and gemcitabine.
The treatment of chemotherapy-induced acrylemia is dose-dependent. To treat chemotherapy-induced acrylemia, symptomatic treatment is done with antihistaminic and analgesic medications. Edema can also be used.
The National Center for Biotechnology Information, (NCBI) states that capecitabine treatment can reduce the chance of developing HFS in 60% of patients.
On September 20, 2020 the Central National Investigations Oncology(CNIO) identified genetic variants linked to HFS in capecitabine therapy.
Request a sample to get more information on the {{Keyword}} market (Use Corporate email ID to Get Higher Priority): https://market.us/report/chemotherapy-induced-acral-erythema-treatment-market/request-sample/
Detailed Segmentation
Global chemotherapy-induced erythema market segmented based on – Product Types and Distribution Channels. Below is a detailed segmental description.
Based On Product Types:
• Analgesics
• Anti-inflammatory & Anti-edematous Agents
• Antihistaminic
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Oral/Topical Glucocorticoids
• Pyridoxine (Vitamin B6)
• Cold Compression Therapy
• Other Product Types
Based On Distribution Channels:
• Pharmacy & Drugstores
• Hospital Pharmacies
• Online Drug Stores
Based upon Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa
Market Dynamics –
Market Drivers for Global Chemotherapy-Induced Acral Erythema Treatment Market
As a result, the global market for chemotherapy-induced acral allergy treatment is growing. This could help to increase the revenue growth in the global chemotherapy-induced acne treatment market over the next few years.
According to the 2015 World Health Organization (WHO), cancer factsheet, the global prevalence rate of cancer is expected to rise by 70% in the next 20 years. This may have a positive effect on the growth of the global market for chemotherapy-induced erythema treatments.
Competitive Landscape –
Taro Pharmaceutical Industries Ltd., Oceanside Pharmaceuticals Inc., Pfizer, Novartis AG, A-S Medication Solutions LLC., Preferred Pharmaceuticals Inc., Syntex Pharmaceuticals Inc., Valeant Canada LP, Technilab Pharma Inc., and Allergan Plc., among others. are key players in this market. To maintain their competitive edge, these key industry players are now focusing their efforts on mergers, partnerships and acquisitions, product development, and collaboration strategies.
